文献速递艾滋病与性传播感染

阴道雌二醇对HIV感染女性绝经泌尿生殖综合征、阴道微生物组及黏膜免疫介质的影响

Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV.
PubMed 文献 · Clin Infect Dis · 2026-01-01

两组复合阴道症状指数均下降,但雌二醇组降幅显著更大(P<.0001),且阴道成熟指数与最困扰症状仅雌二醇组显著改善,微生物组与黏膜免疫介质无显著变化。

要点

  • 阴道雌二醇可显著改善HIV感染绝经女性的泌尿生殖综合征症状。
  • 阴道成熟指数与最困扰症状的改善仅见于雌二醇组。
  • 阴道微生物组与黏膜免疫介质在12周内未见显著变化。

核心结论

  • 阴道雌二醇对HIV感染绝经女性的绝经泌尿生殖综合征症状改善幅度显著大于不治疗。
  • 雌二醇与较年轻年龄均与复合阴道症状指数改善相关。
  • 阴道成熟指数与最困扰症状仅在雌二醇组显著改善,微生物组与黏膜免疫介质无显著变化。

研究设计与样本

  • 随机、开放标签、对照试验,将绝经HIV感染女性按1:1随机分配至12周阴道雌二醇组(n=25)或不治疗组(n=26)。
  • 纳入标准为过去一个月内至少有一种泌尿生殖症状(干燥、瘙痒、刺激、酸痛或性交痛)且存在临床萎缩。
  • 主要结局为基线至第12周复合阴道症状指数(VSI,评分0-3)平均严重程度差异。

主要发现

  • 两组VSI均显著下降,但雌二醇组下降幅度显著更大(P<.0001)。
  • 阴道成熟指数和最困扰症状仅在雌二醇组显著改善。
  • 阴道微生物组和黏膜免疫介质未见显著变化。

关键数值与推荐

  • 主要结局为基线至第12周复合阴道症状指数(VSI)平均严重程度差异,评分范围0-3。
  • 两组VSI下降幅度比较P<.0001,雌二醇组显著更大。

临床怎么用

  • 对于接受抗逆转录病毒治疗的绝经HIV感染女性,阴道雌二醇可考虑用于改善绝经泌尿生殖综合征症状。
  • 治疗或许应更早启动,但需更大规模临床试验验证。

局限性

  • 研究为开放标签设计,样本量较小(雌二醇组25例,不治疗组26例)。
  • 随访时间为12周,未评估长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with human immunodeficiency virus (HIV, WWH) experience early onset menopause and symptoms may impact antiretroviral therapy (ART) adherence. Vaginal estradiol is safe and effective for treatment of the genitourinary syndrome of menopause (GSM) but has not been studied in WWH. The study objective was to test whether vaginal estradiol would improve GSM symptoms in menopausal WWH. METHODS: Menopausal WWH were randomized 1:1 to 12 weeks of open-label vaginal estradiol (n = 25) versus no treatment (n = 26). Participants had at least 1 GSM vulvovaginal symptom in the month prior (dryness, itching, irritation, soreness, or dyspareunia) and clinical atrophy. The primary outcome was difference in mean symptom severity (scale 0-3) defined by the composite vaginal symptom index (VSI) between baseline and week 12. Changes in severity of participants' most bothersome symptom (MBS), vaginal maturation index (VMI), vaginal microbiome, and mucosal immune mediators were assessed. Results were compared by paired t test or Wilcoxon signed rank tests; a mixed effect model examined differences in VSI improvement between groups. RESULTS: Mean age was 59 years, 78% self-reported as Black, and all were on ART. Both groups had significant reductions in VSI, however the magnitude was significantly greater in the estradiol group (P < .0001). Estradiol and younger age were associated with VSI improvement. VMI and MBS improved significantly only in the estradiol group. There were no significant changes in the microbiome or mucosal mediators. CONCLUSIONS: The favorable response to estradiol suggests that treatment perhaps initiated earlier may be beneficial for GSM in WWH and should be studied in larger clinical trials.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Murphy K, Gromisch M, Connolly J, et al. Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV. Clin Infect Dis. 2026. PMID: 41355723. doi:10.1093/cid/ciaf669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。